| For: | Pirola L. Elafibranor, a dual PPARα and PPARδ agonist, reduces alcohol-associated liver disease: Lessons from a mouse model. World J Gastroenterol 2025; 31(4): 99312 [PMID: 39877705 DOI: 10.3748/wjg.v31.i4.99312] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v31/i4/99312.htm |
| Number | Citing Articles |
| 1 |
Alka Singh, Ansab Akhtar, Prashant Shukla. Exploring hepatic stellate cell-driven fibrosis: therapeutic advances and future perspectives. ADMET and DMPK 2025; 13(4) doi: 10.5599/admet.2874
|
| 2 |
Min Guo, Jian-nan Cao, Xiao-dong Li, Ling Jin. Key Transcription Factors: Avenue for Treating Alcoholic Liver Disease. Current Medical Science 2025; 45(4) doi: 10.1007/s11596-025-00079-3
|
| 3 |
Yongsheng Fang, Han Liu, Fakun Jiang, Qian Lu, Bangrui Huang, Chuanjun Mao, Qian Long, Qixin Zhou, Xiaodong Yang, Jun Cao, Wenyong Xiong. Euphorbia factor L3 ameliorates hepatic steatosis by activating LKB1-AMPK signaling pathway-regulated lipid metabolism. Bioorganic Chemistry 2026; 179 doi: 10.1016/j.bioorg.2026.110008
|
| 4 |
Yue Feng, PanShiLi Han, Tao Liu, YanHang Gao. MetALD: new insights and unraveling therapeutic potential. Metabolism and Target Organ Damage 2025; 5(3) doi: 10.20517/mtod.2025.65
|